{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the a-synuclein gene promote a-synuclein aggregation, which is a major event in the development of Lewy body pathology in PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The general class of assay used (aggregation assay) effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "judgment": "Yes",
          "reasoning": "The assay used (aggregation assay) is appropriate for studying the disease mechanism (a-synuclein aggregation) in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly mention the inclusion of basic controls or replicates for this assay.",
          "judgment": "No",
          "reasoning": "The paper does not provide sufficient information on basic controls or replicates for this assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The aggregation assay is a broadly accepted and standard technique in the field for studying a-synuclein aggregation.",
          "judgment": "Yes",
          "reasoning": "The assay has been historically validated in the field as a standard technique for studying protein aggregation.",
          "next_step_or_outcome": "The functional evidence strength is PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T variant promotes a-synuclein aggregation, which is a key mechanism in PD pathology. The functional evidence from the aggregation assay, although not fully detailed in controls, is supported by the assay's established validity in the field. Therefore, the evidence strength is PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the a-synuclein gene promote a-synuclein aggregation, which is a major event in the development of Lewy body pathology in PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The general class of assay used (aggregation assay) effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "judgment": "Yes",
          "reasoning": "The assay used (aggregation assay) is appropriate for studying the disease mechanism (a-synuclein aggregation) in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly mention the inclusion of basic controls or replicates for this assay.",
          "judgment": "No",
          "reasoning": "The paper does not provide sufficient information on basic controls or replicates for this assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The aggregation assay is a broadly accepted and standard technique in the field for studying a-synuclein aggregation.",
          "judgment": "Yes",
          "reasoning": "The assay has been historically validated in the field as a standard technique for studying protein aggregation.",
          "next_step_or_outcome": "The functional evidence strength is PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant promotes a-synuclein aggregation, which is a key mechanism in PD pathology. The functional evidence from the aggregation assay, although not fully detailed in controls, is supported by the assay's established validity in the field. Therefore, the evidence strength is PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the a-synuclein gene promote a-synuclein aggregation, which is a major event in the development of Lewy body pathology in PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The general class of assay used (aggregation assay) effectively models the disease pathogenesis/mechanism defined in Step 1.",
          "judgment": "Yes",
          "reasoning": "The assay used (aggregation assay) is appropriate for studying the disease mechanism (a-synuclein aggregation) in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly mention the inclusion of basic controls or replicates for this assay.",
          "judgment": "No",
          "reasoning": "The paper does not provide sufficient information on basic controls or replicates for this assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The aggregation assay is a broadly accepted and standard technique in the field for studying a-synuclein aggregation.",
          "judgment": "Yes",
          "reasoning": "The assay has been historically validated in the field as a standard technique for studying protein aggregation.",
          "next_step_or_outcome": "The functional evidence strength is PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The E46K variant promotes a-synuclein aggregation, which is a key mechanism in PD pathology. The functional evidence from the aggregation assay, although not fully detailed in controls, is supported by the assay's established validity in the field. Therefore, the evidence strength is PS3_supporting."
    }
  ]
}